Physician

Sharon A Goble, M.D.

According to 2025 Medicare claims, Sharon Goble, M.D. (NPI: 1255394417) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23235-4730.

Goble's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 676 traditional Medicare patients, billed 105,271 HCPCS/CPT codes, and received $2,124,117 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,675 prescription claims across 324 beneficiaries totaling $2,070,565 in drug costs, led by Revlimid (Lenalidomide). DME data shows 43 claims. Open Payments data shows 11 records totaling $2,047. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $741,036 to $2,070,565. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	890	104,372	$1,538,936
2016	777	106,482	$1,832,223
2017	873	127,007	$2,149,160
2018	931	170,103	$2,496,233
2019	886	120,132	$2,053,684
2020	863	143,823	$2,623,946
2021	832	133,649	$2,492,010
2022	756	116,090	$2,179,806
2023	728	132,962	$2,395,288
2024	676	105,271	$2,124,117

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	195	1,193	$741,036
2016	207	1,331	$918,535
2017	253	1,475	$1,013,064
2018	269	1,529	$2,022,257
2019	277	1,699	$2,967,696
2020	263	1,612	$2,875,262
2021	270	1,669	$2,851,899
2022	287	1,609	$2,386,434
2023	301	1,734	$2,058,143
2024	324	1,675	$2,070,565

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	225	$39,566
2016	N/R	104	$40,586
2017	11	125	$37,355
2018	N/R	144	$20,104
2019	N/R	133	$16,244
2020	N/R	120	$8,576
2021	N/R	53	$4,191
2022	N/R	138	$4,901
2023	N/R	52	$6,303
2024	N/R	43	$825

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	92	295	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	181	448	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	297	439	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	194	230	$12
96372	Injection of drug or substance under skin or into muscle	79	157	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	22	616	$408,953
Pomalyst	Pomalidomide	17	476	$396,459
Imbruvica	Ibrutinib	24	694	$307,940
Verzenio	Abemaciclib	14	392	$205,393
Lonsurf	Trifluridine/Tipiracil Hcl	11	308	$102,964

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$405
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$245
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$210	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$1,838	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sharon A. Goble, M.D.?

Tedicare shows public-source Medicare data for Sharon A. Goble, M.D. (NPI 1255394417), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sharon A. Goble, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sharon A. Goble, M.D.?

Sharon A. Goble, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Sharon A. Goble, M.D. have Open Payments data?

Sharon A. Goble, M.D. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.